image description

Tag: Olumiant

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […] Read More

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […] Read More